Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02506465 · ClinicalTrials.gov registry record · NA

Pivotal Study to Assess the Safety and Effectiveness of the iTind Device

A NA study of Benign Prostate Hyperplasia, sponsored by Medi-Tate.

Completed
Registry status
NA
Development phase
185
Enrollment target
13
Study locations

NCT02506465 is a NA study of Benign Prostate Hyperplasia that has completed, run by Medi-Tate. The registered enrollment target is 185 participants. The trial reports 13 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02506465, a NA study of Benign Prostate Hyperplasia, has completed, sponsored by Medi-Tate.

COMPLETED
Registry status
NA
Development phase
185 participants
Enrollment target
13
Study locations

Study Summary

The study objectives are to demonstrate the efficacy and safety of the Medi-Tate iTIND as compared to control group (catheter only).

Interventions

  • DEVICE iTIND
  • PROCEDURE Sham Arm

Study Locations (13)

New York

  • Methodist Hospital - Brooklyn
  • Winthrop University - Garden City
  • St John's Episcopal - Lawrence
  • Integrated Medical Professionals - Long Island City
  • Manhattan Medical research - Manhattan
  • Weill cornell - Manhattan
  • Premier Urology Group - New York
  • Primier Medical Center - Poughkeepsie

Florida

  • Clinical Research Center of Florida - Pompano Beach

Maryland

  • Chesapeake Urology Research Associates - Baltimore

South Carolina

  • Carolina Uro Research Center - Myrtle Beach

Quebec

  • CIUSS de l'Estrie-CHUS - Sherbrooke

Other

  • Toronto - Toronto

Trial Details

FieldValue
Enrollment Target 185 participants
Start Date 2015-07
Est. Completion 2018-10
Phase NA

Sponsor

Medi-Tate

2 total trials

What the Registry Record Tells You About NCT02506465

The ClinicalTrials.gov registry entry for NCT02506465 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medi-Tate, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Benign Prostate Hyperplasia appearing as the primary indexed condition, and to 2 interventions - of which iTIND is the first listed.

NCT02506465 reports 13 study locations spanning 6 distinct geographic areas - top geographies include New York, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT02506465 about?

NCT02506465 is a clinical study titled "Pivotal Study to Assess the Safety and Effectiveness of the iTind Device". The study objectives are to demonstrate the efficacy and safety of the Medi-Tate iTIND as compared to control group (catheter only).

What is the current status of trial NCT02506465?

This trial is currently completed. It is a NA study. The enrollment target is 185 participants. The study started on 2015-07. Estimated completion is 2018-10.

What conditions does trial NCT02506465 study?

This clinical trial studies the following conditions: Benign Prostate Hyperplasia.

What interventions are being tested in trial NCT02506465?

The interventions under investigation include: iTIND (DEVICE), Sham Arm (PROCEDURE).

Who is sponsoring clinical trial NCT02506465?

This trial is sponsored by Medi-Tate, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02506465 being conducted?

This trial has 13 study locations across Florida, Maryland, New York, South Carolina, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Benign Prostate Hyperplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.